Radiotherapy with continued EGFR‐TKIs for oligoprogressive disease in EGFR‐mutated non‐small cell lung cancer: A real‐world study
Authors:
Open Access
- 5 June 2022
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 12 (1) , 266-273
Abstract
Background: Epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) develops resistance to tyrosine kinase inhibitors (TKIs). Here, we evaluated the efficacy of radiotherapy and continuation of TKIs in patients with advanced NSCLC with oligoprogression after EGFR‐TKIs.Methods: From January 2011 to January 2019, 33 patients with EGFR‐mutated NSCLC on TKIs were treated by radiotherapy and continuation of TKIs for oligoprogressive disease. The primary endpoints were median progression‐free survival 1 (mPFS1), mPFS2, and median overall survival (mOS). PFS1 was measured from the start of EGFR‐TKIs therapy to the oligoprogression of the disease. PFS2 was measured from the date of oligoprogression to the further progression of the disease, while OS was calculated from oligoprogression to death from any cause or was censored at the last follow‐up date.Result: The mPFS1, mPFS2, and mOS were 11.0 (95% CI, 4.4–17.6), 6.5 (95% CI, 1.4–11.6) and 21.8 (95% CI, 14.8–28.8) months, respectively. Univariate analysis showed that EGFR mutation type (p = 0.024), radiotherapy method (p = 0.001), and performance status (p = 0.017) were significantly correlated with PFS2. Univariate analysis showed that sex (p = 0.038), smoking history (p = 0.031), EGFR mutation type (p = 0.012), and radiotherapy method (p = 0.009) were significantly correlated with OS. Multivariate analysis suggested that radiotherapy method (p = 0.001) and performance status (p = 0.048) were prognostic factors for PFS2, and radiotherapy method (p = 0.040) was a prognostic factor for OS.Conclusion: Radiotherapy with continued TKIs is effective for EGFR‐mutated NSCLC with oligoprogression, and it should be conducted as soon as possible. T790M+ patients have higher sensitivity to radiotherapy, and patients with good performance status and stereotactic body radiation therapy have better PFS2 and OS.Keywords
This publication has 18 references indexed in Scilit:
- Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized StudyJournal of Clinical Oncology, 2019
- The current state of oligometastatic and oligoprogressive non-small cell lung cancerJournal of Thoracic Disease, 2018
- The biology and management of non-small cell lung cancerNature, 2018
- CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trialsAnnals of Oncology, 2017
- Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung CancerJAMA Oncology, 2017
- The Role of Radiotherapy in Epidermal Growth Factor Receptor Mutation-positive Patients with Oligoprogression: A Matched-cohort AnalysisClinical Oncology, 2017
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung CancerNew England Journal of Medicine, 2017
- [Ionizing Radiation Reduces TKI Resistance Caused by T790M Mutation in NSCLC Cell Lines].2015
- Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failureLung Cancer, 2011
- Oligometastases.Journal of Clinical Oncology, 1995